Log in to search using one of your social media accounts:

 

ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

CONCLUSIONS: The combination of TBx and SBx achieved the best results for the detection and prognosis of PCa-s. The use of SBx alone would have missed the detection of PCa-s in 12% of patients. PMID: 29463177 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
CONCLUSIONS: Low-dose brachytherapy offers good short- to intermediate-term cancer control in selected men with localized PCa. Further studies are needed for safety analyses and for comparison with other treatment modalities. PMID: 29463165 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Objectives: The role of the tumor growth fraction has been investigated poorly in metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to assess whether some prostate-specific antigen (PSA)-related variables of tumor cell kinetics predict the overall survival in early and late mCRPC, and to explore changes in the tumor growth fraction after chemotherapy. Methods: A retrospective analysis of 3 tumor cell kinetic variables in patients with mCRPC receiving first-line chemotherapy has been performed. The PSA-related tumor growth rate, the log ratio, and the tumor response have been measured a...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
The American Institute of Ultrasound in Medicine (AIUM) has announced its 2018...Read more on AuntMinnie.comRelated Reading: AIUM publishes guidance for improving ob/gyn US AIUM: Is MRI really needed after MSK ultrasound? AIUM: Machine learning may aid breast ultrasound reads AIUM: NIH prepares for potential re-emergence of Zika virus AIUM: Contrast US biopsy combo finds high-grade prostate cancer
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
A team of international researchers has successfully tested a risk prediction...Read more on AuntMinnie.comRelated Reading: MRI confirms prostate cancer with lower dose of GBCA Biomarker test could direct MRI use for prostate cancer Luminal water MRI could be best for prostate cancer MRI can replace biopsy for prostate cancer surveillance MRI can help avoid unnecessary prostate cancer biopsies
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
CONCLUSION: These results position FENDRR/miR-18a-5p/RUNX1 as a potential therapeutic target and biomarker for PCa. PMID: 29465000 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Authors: Umbaugh CS, Diaz-Quiñones A, Neto MF, Shearer JJ, Figueiredo ML Abstract Laminin receptor (67 LR) is a 67 kDa protein derived from a 37 kDa precursor (37 LR). 37/67 LR is a strong clinical correlate for progression, aggression, and chemotherapeutic relapse of several cancers including breast, prostate, and colon. The ability of 37/67 LR to promote cancer cell aggressiveness is further increased by its ability to transduce physiochemical and mechanosensing signals in endothelial cells and modulate angiogenesis. Recently, it was demonstrated that 37/67 LR modulates the anti-angiogenic potential of the...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: Men with higher BMI and weight at early middle age have an increased risk of PCa diagnosis and death after adjusting for PSA. However, in a multi-variable numerical statistical model, BMI and weight do not importantly improve the predictive accuracy of PSA. Risk-stratification of screening should be based on PSA without reference to anthropometrics. PMID: 29464033 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD Abstract The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer. Recognition that PSA testing has caused over diagnosis and over treatment of prostate cancer has generated considerable controversy over its value, and has spurred efforts to identify prognostic biomarkers to distinguish patien...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion: The DAPK/CIP2A complex is involved in GAS6/AXL-related Schwann cell proliferation. CIP2A inhibits PP2A activity, which results in p-DAPK(S308) maintenance and promotes Schwann cell proliferation. CIP2A is a potential target for the treatment of nerve injury after RP. PMID: 29464081 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Clinical Trials | Pharmaceuticals | Prednisone | Prostate Cancer | Statistics